WO1999047153A3 - UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY rho GTPase FUNCTION INHIBITORS - Google Patents

UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY rho GTPase FUNCTION INHIBITORS Download PDF

Info

Publication number
WO1999047153A3
WO1999047153A3 PCT/US1999/006185 US9906185W WO9947153A3 WO 1999047153 A3 WO1999047153 A3 WO 1999047153A3 US 9906185 W US9906185 W US 9906185W WO 9947153 A3 WO9947153 A3 WO 9947153A3
Authority
WO
WIPO (PCT)
Prior art keywords
rho gtpase
nitric oxide
function inhibitors
endothelial cell
oxide synthase
Prior art date
Application number
PCT/US1999/006185
Other languages
French (fr)
Other versions
WO1999047153A2 (en
Inventor
James K Liao
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Priority to AU31075/99A priority Critical patent/AU3107599A/en
Publication of WO1999047153A2 publication Critical patent/WO1999047153A2/en
Publication of WO1999047153A3 publication Critical patent/WO1999047153A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A use for rho GTPase function inhibitors is provided. In the instant invention, rho GTPase function inhibitors are found to upregulate endothelial cell Nitric Oxide Synthase activity. As a result, rho GTPase function inhibitors are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.
PCT/US1999/006185 1998-03-19 1999-03-19 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY rho GTPase FUNCTION INHIBITORS WO1999047153A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU31075/99A AU3107599A (en) 1998-03-19 1999-03-19 Upregulation of type iii endothelial cell nitric oxide synthase by (rho) gtpase function inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US7877498P 1998-03-19 1998-03-19
US60/078,774 1998-03-19
US9261898A 1998-06-05 1998-06-05
US09/092,618 1998-06-05
US09/132,849 1998-08-11
US09/132,849 US6180597B1 (en) 1998-03-19 1998-08-11 Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors

Publications (2)

Publication Number Publication Date
WO1999047153A2 WO1999047153A2 (en) 1999-09-23
WO1999047153A3 true WO1999047153A3 (en) 1999-11-18

Family

ID=27373348

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006185 WO1999047153A2 (en) 1998-03-19 1999-03-19 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY rho GTPase FUNCTION INHIBITORS

Country Status (3)

Country Link
US (1) US6180597B1 (en)
AU (1) AU3107599A (en)
WO (1) WO1999047153A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812253B2 (en) 2001-02-13 2004-11-02 Aventis Pharma Deutschland Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239172B1 (en) 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5968983A (en) 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US20080233098A1 (en) * 1997-10-31 2008-09-25 Mckerracher Lisa RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
WO2000003746A2 (en) * 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US7169783B2 (en) * 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
JP2002539257A (en) 1999-03-19 2002-11-19 イーノス・ファーマシューティカルス・インコーポレーテッド Increased drug bioavailability in the brain
WO2002055027A2 (en) * 2001-01-11 2002-07-18 The Research Foundation Of State University Of New York Placebo effect and relaxation response
PE20020870A1 (en) 2001-02-13 2002-11-18 Aventis Pharma Gmbh 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL ACILATED AMINES
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (en) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-TETRAHYDRONAFTIL ACILATED AMINES
AU2002349411A1 (en) * 2001-11-30 2003-06-17 Asahi Kasei Pharma Corporation Remedies for primary pulmonary hypertension
MXPA04009033A (en) * 2002-03-18 2005-01-25 Pharmacia Corp Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative.
PL373029A1 (en) * 2002-03-18 2005-08-08 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
HUE027779T2 (en) 2002-05-09 2016-11-28 Brigham & Womens Hospital Inc 1L1RL-1 as a cardiovascular disease marker
US7105513B2 (en) 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
AU2003284962B2 (en) * 2002-10-24 2009-04-02 Palmetto Pharmaceuticals, Llc Sustained release L-arginine formulations and methods of manufacture and use
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
WO2005035001A1 (en) * 2003-09-29 2005-04-21 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US7132536B2 (en) 2003-04-24 2006-11-07 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
DK1708690T3 (en) 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
CN101163489A (en) * 2004-04-23 2008-04-16 细胞基因公司 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
KR20070084270A (en) * 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. Stable tablet formulation
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
US7893050B2 (en) 2005-10-26 2011-02-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US20070264130A1 (en) * 2006-01-27 2007-11-15 Phluid, Inc. Infusion Pumps and Methods for Use
EP1905764A1 (en) 2006-09-30 2008-04-02 Sanofi-Aventis Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
JP2010507387A (en) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド Novel siRNA and method of using the same
EP1923062A1 (en) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
JP5646997B2 (en) 2007-10-03 2014-12-24 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Novel siRNA structure
WO2009055421A1 (en) * 2007-10-22 2009-04-30 Alseres Pharmaceuticals, Inc. Chimeric c3-like rho antagonist cardiac therapeutic
US8986253B2 (en) * 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US20090287180A1 (en) * 2008-05-19 2009-11-19 Diperna Paul M Disposable pump reservoir and related methods
US8408421B2 (en) * 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) * 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Solute concentration measurement device and related methods
WO2011014704A2 (en) * 2009-07-30 2011-02-03 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN102949725B (en) * 2011-11-30 2015-08-12 天津金耀集团有限公司 A kind of injectable pharmaceutical compositions containing glucocorticoid and no inhibitor
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (en) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4351844A (en) 1980-02-04 1982-09-28 Merck & Co., Inc. Hypocholesterolemic hydrogenation products and process of preparation
DK149080C (en) 1980-06-06 1986-07-28 Sankyo Co METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US5116870A (en) 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
DE3833008A1 (en) * 1988-09-29 1990-04-05 Goedecke Ag PYRROLOCARBOZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT
US4965200A (en) 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5084482A (en) 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5135935A (en) 1991-05-17 1992-08-04 Merck & Co., Inc. Squalene synthetase inhibitors
JPH07504887A (en) 1991-11-22 1995-06-01 リポジェニックス，インコーポレイテッド Tocotrienols and tocotrienol-like compounds and methods of using them
AU3731293A (en) * 1992-02-24 1993-09-13 Smithkline Beecham Corporation Protein kinase c inhibitor
US5514696A (en) 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
EP0647446A4 (en) 1993-04-19 1995-11-15 Green Cross Corp Novel medicinal use of dihydropyridine derivative.
US5602098A (en) * 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5945452A (en) 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5428070A (en) 1993-06-11 1995-06-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity
US5475029A (en) 1993-07-08 1995-12-12 The Board Of Trustees Of The Leland Stanford Junior University Farnesyl compounds as cholesterol lowering agents
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US6369103B1 (en) 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5470832A (en) * 1994-01-31 1995-11-28 Merck & Co., Inc. Inhibitors of geranylgeranyl-protein transferase
US5756453A (en) * 1994-08-03 1998-05-26 Cell Therapeutics, Inc. Use of angiogenic lipids for vascularizing tissue
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5968983A (en) 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US5543430A (en) 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
JPH09183797A (en) 1995-12-28 1997-07-15 Kirin Brewery Co Ltd Physiologically active protein rhotekin
US5912019A (en) 1997-02-07 1999-06-15 Musc Foundation For Research Development Compounds for reducing ischemia/reperfusion injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LAUFS U ET AL: "Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1997 DEC 12) 272 (50) 31725-9., XP002091893 *
LAUFS U ET AL: "Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 SEP 11) 273 (37) 24266-71., XP002116831 *
LOPEZ-ONGIL E.A.: "Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 271, no. 3, September 1996 (1996-09-01), pages H1072-8, XP002116834 *
OHARA E.A.: "Regulation of endothelial constitutive nitric oxide synthase by protein C", HYPERTENSION, vol. 25, no. 3, March 1995 (1995-03-01), pages 415 - 420, XP002116832 *
STROES E.A.: "Cyclosporin A increases nitric oxide activity in vivo", HYPERTENSION, vol. 29, no. 2, February 1997 (1997-02-01), pages 570 - 575, XP002116833 *
YANO E.A.: "Involvement of rho p21 in cyclic strain induced tyrosine phosphorylation of focal adhesion kinase (pp125-FAK), morphological changes and migration of endothelial cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 224, 1996, ORLANDO, FL US, pages 508 - 515, XP002116835 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812253B2 (en) 2001-02-13 2004-11-02 Aventis Pharma Deutschland Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Also Published As

Publication number Publication date
US6180597B1 (en) 2001-01-30
AU3107599A (en) 1999-10-11
WO1999047153A2 (en) 1999-09-23

Similar Documents

Publication Publication Date Title
WO1999047153A3 (en) UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY rho GTPase FUNCTION INHIBITORS
WO2000003746A3 (en) Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
DE69910045D1 (en) NEW HETEROAROMATIC FRUCTOSE 1,6-BISPHOSPHATASE INHIBITORS
MXPA02010068A (en) Halogentated 2 amino 5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors.
WO2002022559A3 (en) 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
TW200616933A (en) Benzoic acid derivatives as non-nucleoside reverse transcriptase inhibitors
HK1074395A1 (en) Use of the metabolite of valsartan to inhibit platelet aggregation
EP1721608A3 (en) Upregulation of type III endothelial cell nitric oxide synthase by HMG-CoA reductase inhibitors
EP1090635A3 (en) Use of ferulic acid for treating hypertension
RU2002106186A (en) An agent with anti-ischemic, antihypertensive, antiarrhythmic and nootropic activity
CY1112438T1 (en) METHOD OF TREATMENT OF ACUTE RENAL DEFICIENCY WITH SOLUBLE THROMBODOULINE
RU2005121615A (en) GEAR CIRCUIT FOR SYNCHRONIZATION BLOCK
RU2001121348A (en) ANTINAKIPIN
RU2003117315A (en) METHOD FOR DETERMINING THE ADDITIONAL BYPASS ZONE OF THE RELATIVE RAIL CHAIN
Skurvydas et al. THE EFFECT OF TWO STRETCH-SHORTENING EXERCISE BOUTS PERFORMED WITHIN 60 MIN ON MUSCLE FATIGUE AND DAMAGE
Livadariu TUE. T-583/19. Electrolux Home Products v. EUIPO and D. Consult. The Word Mark of the European Union Frigidaire. Preclusion. Use of the Trademark in US Military Bases on the Territory of the European Union. No Actual Use of the Trademark
WO2004047762A3 (en) Methods for treating cancer using porimin as a target
RU2002100623A (en) Lightweight refractory
RU99100912A (en) METHOD FOR PREDICTING POSTOPERATIVE HEAVY DISTURBANCES OF EXTERNAL RESPIRATION FUNCTION AT LUNG RESECTIONS
RU99109765A (en) SPACE COVERING PLATE
RU2000110752A (en) METHOD FOR PREDICTING EFFECTIVENESS OF TREATMENT OF COGNITIVE DISORDERS BY CEREBROLYSIN
Reed et al. A Rare Chance for Israeli-Palestinian Progress
ПЕРЕГРУППИРОВКИ ÌÀÑÑ-ÑÏÅÊÒÐÎÌÅÒÐÈ× ÅÑÊÎÅ ÈÇÓ× ÅÍÈÅ ÖÈÊËÎÏÐÎÏÈË-ÀË-ËÈËÜÍÎÉ ÏÅÐÅÃÐÓÏÏÈÐÎÂÊÈ Â N-ÔÎÐÌÈË-2, 2, 5-ÒÐÈÌÅÒÈË-4, 4-ÄÈÕËÎÐÖÈÊËÎÏÐÎÏÀÍ [Ñ] ÕÈÍÎËÈÍÀÕ
совещании адмирал Эссен ÈÑÒÎÐÈß ÑÓÄÎÑÒÐÎÅÍÈß
RU2001110013A (en) Low temperature soldering flux

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase